Relação entre terapia de reposição hormonal no climatério e o desenvolvimento de neoplasias.

Climacteric, a period of transition between the reproductive cycle (menacme) and the non-reproductive cycle (senility or senectude), can be characterized as a period in which there is a decrease in estrogen production by the woman between the fourth and sixth decades of life, which can lead to endocrinopathies. Hormone replacement therapy (HRT) aims to restore estrogen levels, and this article aims to address the risks and benefits of using this therapy. It is known that HRT is related to the occurrence of vasomotor symptoms, irritability, insomnia, memory alterations, emotional lability, menstrual irregularity, dyspaurenia, cardiovascular events, dementia, urinary incontinence and the onset of breast and endometrial neoplasms, the main focus of this work . According to the Women's Health Initiative (WHI) 2002, 15 million American women were already using HRT. According to the KEEPS and ELITE studies, HRT should be started on the perimenopause (50 - 59 years) or up to 6-10 years of menopause. The lowest effective dose (individually calculated) is used as the effective replacement dose. Replacement of estrogen and progestogens presented a higher risk of CA of the breast in relation to the replacement of isolated estrogen. However, the use of progestogens has been shown to be of greater benefit in women with a history of endometriosis or endometrial CA. The HRT decision must respect the physiological and family history of each woman.